# Harrison-AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/harrison-ai-pty

- Industry: Medical Devices & Equipment
- Headquarters: Sydney, Australia
- Website: www.harrison.ai
- Total disclosed funding: $233M
- Latest round: Series C (Feb 11, 2025)
- Investors on record: 12

## About

Harrison-AI Pty Ltd, based in Australia, develops advanced AI-powered diagnostic support solutions tailored for the healthcare sector, enhancing clinical accuracy and efficiency in medical imaging.Founded in 2018, Harrison-AI Pty Ltd specializes in AI-driven diagnostic support for healthcare, primarily focusing on medical imaging technologies. The company was co-founded by Aengus Tran and Dimitry Tran. Its headquarters is located in Sydney, Australia. To date, Harrison-AI has completed a total of 5 deals, with its most recent funding round being a Series C, raising AUD 179 mn on February 11, 2025, from various investors including Aware Super and Horizons Ventures.Harrison.ai specializes in developing advanced AI-powered diagnostic support solutions for the healthcare sector, particularly in medical imaging for radiology and pathology. Their flagship products, Annalise.ai and Franklin.ai, are designed to assist clinicians in delivering faster and more accurate diagnoses, addressing challenges such as increasing clinical demands and skills shortages in healthcare. The solutions are utilized by hospitals and clinics, mainly in Australia, the United States, and the United Kingdom, enhancing the efficiency of medical data analysis and supporting timely patient care.In the year 2023, Harrison.ai reported a revenue of AUD 3,322,244.40, with an EBITDA of AUD -23,160,770.50. The company operates on a B2B revenue model based on partnerships and subscription agreements with healthcare institutions that implement their diagnostic support solutions.Following the AUD 179 mn raised in Series C funding in February 2025, Harrison-AI plans to enhance its global presence and improve its AI-powered diagnostic tools. The company aims to cover a broader range of medical tests to better support healthcare professionals and improve patient outcomes worldwide. This funding will facilitate the development of upcoming products and the expansion into new geographic regions, although specific markets for expansion have not been disclosed.

## Funding rounds

- Series C, Feb 11, 2025, $112M — Aware Super, Horizons Ventures, Blackbird, Alpha JWC Ventures, Ord Minnett, Wollemi Capital Group, National Reconstruction Fund Corporation, ECP Asset Management
- Series B, Dec 1, 2021, $92M — I-MED Radiology Network Limited, Sonic Healthcare Limited, Horizons Ventures, Blackbird, Skip Capital
- Series A, Dec 9, 2019, $29M — Ramsay Health Care Limited Group, Horizons Ventures, Blackbird, Skip Capital

## Investors

- Ramsay Health Care Limited Group — Series A
- Horizons Ventures — Series A, Series B, Series C
- Blackbird (https://capitalatlas.ai/funds/blackbird) — Series A, Series B, Series C
- Skip Capital (https://capitalatlas.ai/funds/skip-capital) — Series A, Series B
- I-MED Radiology Network Limited — Series B
- Sonic Healthcare Limited — Series B
- Aware Super — Series C
- Alpha JWC Ventures (https://capitalatlas.ai/funds/alpha-jwc-ventures) — Series C
- Ord Minnett (https://capitalatlas.ai/funds/ord-minnett) — Series C
- Wollemi Capital Group — Series C
- National Reconstruction Fund Corporation — Series C
- ECP Asset Management — Series C